Oct. 30, 2002 — Digoxin may pose a risk of death for women with heart failure, according to a retrospective analysis published in the Oct. 31 issue of the New England Journal of Medicine. Yet ...

A randomized trial shows no significant difference in the primary endpoint of quality of life at 6 months between treatment with digoxin vs the beta-blocker bisoprolol (Zebeta) in patients with atrial ...

The drug is derived from the foxglove plant (Digitalis purpurea), which was first described as a treatment for “dropsy” — now ...

Low-dose digoxin was generally well tolerated and safe. Last year, results were published from the DIGIT-HF trial, which studied another digitalis glycoside, digitoxin, in patients with advanced HF ...

Heart failure (HF) patients who have reduced or mildly reduced ejection fraction derive better outcomes when low-dose digoxin ...

MADRID, Spain—Adding digitoxin, a cardiac glycoside, to contemporary guideline-directed medical therapy (GDMT) improves clinical outcomes in patients who have heart failure with reduced ejection ...